CSK Tri-Axis Balanced Series II-NP

Mentha × piperita

Peppermint

Tier IICSK Tri-Axis Balanced Series

Target Trait

1.38×

fold-change

Cooling+Sweet+Kokumi balanced tri-axis fold-change

Technical Specifications

SKU

SS-F-M3-02210

Genomic Edits

GC Content

43.5%

Construct Length

4,524 bp

Promoter System

Lipid nanoparticle / Ubiquitin

Expression System

Nanoparticle delivery

Host Strain

LNP-mediated

Receptor Target

TRPM8 + TAS1R2/TAS1R3 + CaSR

IFI Score

138

Pathway Edits

TRPM8 pathway primary gene cluster for cooling (IFI-C) tri-axis component
TAS1R2/TAS1R3 pathway primary gene cluster for sweet (IFI-S) tri-axis component
CaSR pathway primary gene cluster for kokumi (IFI-K) tri-axis component
Tri-axis metabolic flux partitioning hub for concurrent CSK pathway operation
Cross-pathway regulatory circuit for balanced CSK triple-axis expression
Cofactor regeneration system (NADPH, ATP, acetyl-CoA) supporting triple-axis concurrent production

Key Interventions

Triple-axis receptor co-activation: TRPM8, TAS1R2/TAS1R3, and CaSR pathways simultaneously engineeredBalanced tri-axis expression strategy (CSK) with cross-pathway flux managementLNP-mediated delivery of triple-axis mRNA panel for transient expression profiling

IFI Subscale Profile

IFI Profile

IFI-S

—

IFI-U

—

IFI-B

—

IFI-K

—

IFI-C

—

IFI-P

—

IFI-A

—

IFI-F

—

Use Case

Tier II CSK triple-axis construct for advanced multi-modal sensory architecture combining cooling, sweet, and kokumi axes. Suitable for ultra-premium ingredient formulation requiring certification across three simultaneous IFI receptor pathways.

License

$949 · Tier II License

Includes full construct sequence, CRISPR guide designs, pathway edit specifications, flux balance analysis, and IFI validation data.

Already purchased?

Back to Multi-Axis · IFI-M All Modalities